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Introduction: The headache phase of migraine could in selected cases potentially
be treated by surgical decompression of one or more “trigger sites,” located at
frontal, temporal, nasal, and occipital sites. This systematic review with subsequent
meta-analysis aims at critically evaluating the currently available evidence for the surgical
treatment of migraine headache and to determine the effect size of this treatment in a
specific patient population.
Methods: This study was conducted following the PRISMA guidelines. An online
database search was performed. Inclusion was based on studies published between
2000 and March 2018, containing a diagnosis of migraine in compliance with the
classification of the International Headache Society. The treatment must consist of one or
more surgical procedures involving the extracranial nerves and/or arteries with outcome
data available at minimum 6 months.
Results: Eight hundred and forty-seven records were identified after duplicates were
removed, 44 full text articles were assessed and 14 records were selected for inclusion.
A total number of 627 patients were included in the analysis. A proportion of 0.38 of
patients (random effects model, 95% CI [0.30–0.46]) experienced elimination of migraine
headaches at 6–12 months follow-up. Using data from three randomized controlled
trials, the calculated odds ratio for 90–100% elimination of migraine headaches is 21.46
(random effects model, 95% CI [5.64–81.58]) for patients receiving migraine surgery
compared to sham or no surgery.
Conclusions: Migraine surgery leads to elimination of migraine headaches in 38% of
the migraine patients included in this review. However, more elaborate randomized trials
are needed with transparent reporting of patient selection, medication use, and surgical
procedures and implementing detailed and longer follow-up times.
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INTRODUCTION
Rationale
Migraine is one of the most common diseases worldwide,
leading to millions of people taking either preventive or abortive
headache medication on a regular basis (1). It also poses
a significant economic burden as it is ranked among the
most disabling diseases resulting in time lost in the workplace
(2, 3). Surgical treatment of migraine headache might be a
complementary treatment option for a specific group of migraine
patients in which satisfactory pharmacological treatment is not
achieved. The surgical treatment comprises decompression of
several extracranial branches of the trigeminal and occipital nerve
(4) or cauterization of extracranial arteries (5). Although the
official neurological diagnosis of migraine describes symptoms
far more elaborate than episodes of migrainous headache, (6)
this review focuses only on this specific symptom of migraine
that is treated with migraine surgery (6). When using the term
migraine headache (MH), we thus refer to the headache phase
of the complex of migraine symptoms (7). The specific patient
group eligible for migraine surgery may consist of patients
with identifiable extracranial “trigger sites” where their migraine
headache is located. The four identified trigger sites for MH are:
frontal, or forehead, region (F), temporal region (T), occipital
region (O), and nasal area (N). The exact anatomical features,
identification, and surgical approaches have previously been
described extensively (8–14).
The concept of treating migraine headache with extracranial
surgery finds its roots in early surgical history; (15, 16) in the
beginning of the Twentieth century, Oppenheim and Cushing
described elimination and changes of migraine symptoms,
respectively, following extracranial surgical procedures (17,
18). In the years after, references were made to the possible
extracranial origin of certain types of headaches (19) and the
possible surgical treatment through extracranial access points
(16, 20, 21). Following these initial publications, progress in
this research area halted for multiple decades, most likely
because of the advent of still improving pharmacological
treatment options. In recent years, the number of publications
on the surgical treatment of MH has increased, describing new
applications of existing plastic surgery procedures (4, 12, 22, 23)
in addition to new approaches to the extracranial vasculature
(5, 9, 24, 25) and hypotheses about the pathophysiology of
migraine and the involvement of extracranial neurovascular
regions (26, 27). However, despite several headache clinics
applying surgical treatment for migraine, no consensus has
been reached concerning the efficacy of migraine surgery. This
ambiguity may firstly be due to lacking evidence regarding
the exact mechanism of action. It remains puzzling how small
perturbations of extracranial microvascular and/or neuronal
structures can alleviate or even eliminate symptoms in such
a complex disease. Secondly, at least as relevant as the first
point, too often studies focusing on migraine surgery base
their conclusions on insufficiently documentedmethodology and
results (28). Despite these obvious objections to the use of surgical
treatment for a neurological disease, new research is shedding
light on processes that might play a role in the pathophysiological
background of the disease. Whereas migraine was initially
considered as a purely vascular disorder and subsequently
thought to be a purely intracranial neurological disorder, it is now
clear that migraine is a neurovascular disorder, involving both the
brain, nerves and blood vessels (29). Interestingly, more evidence
is emerging for the involvement of the extracranial vessels in the
pathophysiology of migraine (30, 31).
Objectives
The objective of this review is to explore whether surgery aimed
at disrupting the neurovasculature of extracranial trigger sites is
effective for the elimination of migraine headache symptoms in
selected migraine patients. Specifically, the proportion of patients
reporting elimination of MH after follow-up will be calculated
and using data from randomized controlled trials an assessment
of the odds ratio for elimination after surgery vs. sham or no
surgery will be determined.
Research Questions
With this study we aim to answer the research question what the
proportion of migraine patients is reporting elimination of MH
after migraine trigger site surgery and whether surgery compared
to sham or no surgery is more effective in the elimination of MH.
MATERIALS AND METHODS
Study Design
We have reviewed all studies published after 2000 and performed
a systematic review followed by a meta-analysis to determine
the proportion of patients experiencing elimination of migraine
headache symptoms. Additionally, we performed a meta-analysis
on the included randomized controlled trials (RCTs) to calculate
the odds ratio for achieving elimination of headache symptoms
in treatment vs. control groups.
Participants, Interventions, Comparators
Selection of studies was based on in- and exclusion criteria
defined prior to the execution of the search. After selection based
on title and abstract, the full texts of the remaining studies were
reviewed independently by two authors (WH and BB). If both
authors agreed, studies were included. In case of discrepancies, a
discussion followed. In the case that no agreement was reached,
author AV was given the final vote.
Inclusion criteria for this review comprised: studies published
between 2000 andMarch 2018, written in English and performed
in adult human subjects. Studies must contain a diagnosis
of migraine in compliance with the classification of the
International Headache Society (32). For clarification: Behin (33)
included patients with typical MH and transformed migraine, a
chronic daily headache type withmigrainous features that evolves
from episodic migraine and has been classified as a sub form of
migraine (34). Treatment must consist of one or more surgical
procedures involving the extracranial nerves and/or arteries.
Outcome data for the treatment groups must be available for
a minimum of one time-point with a follow-up of at least 6
months. Appropriate study designs included retro/prospective
cohort studies and RCTs. Articles with other study designs were
excluded from further analysis. Studies involving radiosurgery,
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cryosurgery, and any form of nerve stimulation were not
included in this review. Additional exclusion criteria for full
text articles included missing or unclearly defined study design,
patient population, or outcome data. Studies involving treatment
with botulinum toxin injections without surgical intervention
were excluded. All eligible studies were subsequently evaluated
based on their overall methodological quality (35). If the quality
of a study was insufficient based on critical appraisal, it was
excluded from further analysis. The flow diagram for study
selection according to the PRISMA statement guidelines is shown
in Figure 1.
Search Strategy
We performed an online database search on February 17th
2018 combining results from Pubmed, Embase, Medline, Web-
of-Science, Cochrane, and Google Scholar. We used search
terms (variations used depending on the database syntax)
including the following: migraine, surgery, decompression,
cauterization, trigger sites. For full search terms per database
see Supplementary Table 1. Search results were analyzed and
double references were removed. All results were combined in
an EndNote (version X7) database. This study was conducted
following the PRISMA guidelines for systematic reviews and
meta-analyses (36) (see Supplementary Data Sheet 1).
Data Sources, Studies Sections, and Data
Extraction
In migraine surgery literature, outcome assessment is
primarily focused on the changes in parameters directly
related to the headache phase, i.e., intensity, frequency, and
duration. It should be noted that these outcome measures
are specific for surgical literature, and that they therefore
differ from the common endpoints used in pharmacological
migraine studies.
We collected all available data on elimination of MH after
migraine surgery at 6months to 1-year follow-up. The percentage
of patients with elimination of headaches after surgery was taken
from the articles or, if necessary, calculated post hoc based on
patient numbers and outcome data. If a study applied multiple
surgical approaches and performed a qualitative comparison of
procedures (i.e., scopic vs. open approach), we collected outcome
data from both surgical treatment groups.
For the definition of MH elimination, we applied the
following criteria: 100% elimination of migraine headache
intensity, duration and frequency at follow-up from baseline
values. This definition was derived from the measures applied
in the surgical migraine literature. The elimination group was
compared to patients experiencing ≤99% improvement
of the three measures mentioned above at follow-up.
Using these outcomes, we determined the proportion
of patients who experienced elimination of symptoms
at follow-up.
All included studies except for one reported outcome for
the elimination group as 100% elimination of symptoms at
follow-up. The only study reporting an alternate definition
of elimination was Dirnberger and Becker (37), reporting
elimination as 90–100% elimination of headache days. However,
since they report their results as an absolute reduction of
headache days and not a combination of frequency, intensity, and
duration of MH (also known as migraine headache index (MHI)
score which is generally considered to be a less precise measure
than absolute number of headache days), this study was included
in the analysis.
For the meta-analysis of the odds-ratio for elimination
(reported in Figure 3), all articles selected patients eligible for
surgery based on the response to botulinum toxin injection
at the designated trigger sites. Trigger sites were defined as
responsive if MH symptoms at the location reduced at least 50%
in frequency, intensity or duration in response to the botulinum
toxin injection. Although selection with botulinum toxin is not
a current clinically used diagnostic tool or treatment modality
for migraine, it is a common selection feature of migraine
surgery studies and is seen as an indication for treatment
effectivity (38).
Data Reporting and Selection
The heterogeneity in data and outcome reporting was high
between studies. With the exception of Janis et al. (39), Raposio
et al. (12), Guyuron et al. (40), and Jose et al. (41), studies did
not report in detail whether unilateral or bilateral procedures
were performed, therefore no further analysis based on laterality
of the procedure was made. Six out of 14 studies report
performing surgery on three or more surgical sites, among which
are the three RCTs. In some studies, patients could receive
surgery on multiple trigger sites during the same procedure
(42–45). The outcome data were in those cases pooled per
patient without reporting elimination scores for separate sites.
The pooling of this data prohibited any analysis of outcome
per individual trigger site, therefore this was not analyzed
further. The study of Guyuron et al. (40) compares two surgical
approaches for temporal trigger site surgery, performing both
procedures in all patients. In order to ascertain data and
outcomes per patient instead of per site, as this study reported,
we chose to only analyse the decompression surgery data.
For Gfrerer et al. (46), 8 of 35 patients received a second
trigger site procedure after their initial trigger site operation.
Outcome at 1-year follow-up was subsequently analyzed for
the 43 trigger sites operated and was not reported per patient
individually. These data are therefore reported as the total
number and number of eliminations for the sites in Table 2 and
in Figure 2.
Data Analysis
Two separate meta-analyses were performed. For the meta-
analysis of the proportion of patients with elimination of
symptoms at follow-up, a random effects model with a logit
transformation was used to compute the pooled proportion
and associated 95% CI. For individual studies, 95% binomial
proportion CIs were calculated using the Clopper-Pearson
method. RCT and cohort study data was combined to assess
the general percentage of patients reporting elimination after
surgery (48). For the meta-analysis of the treatment effect of
migraine surgery in the included randomized controlled trials, a
random effects model for the odds ratio of migraine surgery was
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FIGURE 1 | Flow diagram of study selection and reasons for exclusion according to PRISMA guidelines.
used to compute the pooled odds ratio and associated 95% CI.
A random effects model was chosen over a fixed effects model
because heterogeneity between studies was expected (49). The
treatment effect of migraine surgery was analyzed by comparing
the proportion of patients with complete elimination of MH
after surgery (calculated as the number of patients experiencing
elimination divided by the total number of patients in the
group) to the proportion of patients experiencing elimination
of symptoms in the control group resulting in the odds
ratio for elimination of MH symptoms after surgery. In both
meta-analyses, the Hartung–Knapp–Sidik–Jonkmanmethod was
applied to estimate the between-study variance, and a continuity
correction of 0.5 was applied in case of studies with zero cell
frequencies. The heterogeneity of combined study results was
assessed using the inconsistency statistic (I2 and confidence
interval of I2) and tested using Cochran’s Q test. For assessment
of publication bias, funnel plots were generated. The meta-
analyses were performed using R version 3.4.3 and the R packages
meta andmetafor.
RESULTS
Study Selection and Characteristics
We identified 847 unique records from six different databases
after removal of duplicates. All identified records were screened
for eligibility by title and abstract. Forty-four full text articles
were reviewed for inclusion. Fourteen studies satisfied all in- and
exclusion criteria and are included in this review (Figure 1).
The general characteristics of the included studies are
summarized in Table 1. A total of 627 patients are included
in this review including treatment and control groups. The
sample size varied from 18 to 108 patients and follow-up period
ranged from 6 months in three studies (12, 33, 37) to 1 year or
more in the other studies. The age of study participants ranged
from 18 to 80 years and percentage of male participants varied
between 2.6 and 27.5%. Surgical approaches to the four distinct
trigger sites were either through an open approach with skin
incision, or via endoscopic approach, also used for cosmetic
surgical applications.
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FIGURE 2 | Proportion of patients with elimination of MH at follow-up. Meta-analysis with forest plot of the proportions of patients with elimination of MH after
migraine surgery at follow-up. Study column reports author, country and year of publication. The total number of treated patients per study is shown with the number
of patients reporting elimination at follow-up. Elimination column reports total number of patients with elimination of MH at follow-up. Total is the total number of
patients included in the surgical arm of the study. The proportion column represents the proportion patients with elimination of symptoms with 95% confidence interval
(95%-CI) with fixed and random effects model weights. Mean proportion for fixed effects model and random effects model with confidence interval given.
Heterogeneity calculations based on the Hartung–Knapp–Sidik–Jonkman estimator with p-value based on Cochran’s Q given.
FIGURE 3 | Odds ratio for elimination of MH symptoms at 1 year follow-up: intervention vs. control groups. Meta-analysis of three RCTs reporting MH elimination
outcomes at 1 year is shown in the figure. Odds ratio for elimination of symptoms in surgery group vs. control group calculated. The surgery column represents the
number of patients with elimination after surgery and the control column represents the number of patients with elimination of MH in the control groups. The total
column reports the total number of patients in the surgery and control groups. Fixed and random effects model final odds ratio is given. OR, odds ratio. 95%-CI,
confidence interval. Heterogeneity calculations based on the Hartung–Knapp–Sidik–Jonkman estimator with p-value based on Cochran’s Q given.
Elimination of Migraine Symptoms at 6–12 Month
Follow-Up
A total number of 565 patients treated with migraine surgery was
included in the analysis, a summary is given in Table 2. Figure 2
shows that a proportion of 0.38 of patients (random effects
model, 95% confidence interval [0.30–0.46], heterogeneity: I2
= 49% [5%; 72%], p = 0.02) reported elimination of MH at
follow-up. The significant p-value for I2 suggests heterogeneity
of the data. This heterogeneity is mainly due to two outliers
with stricter handling of the definition of elimination, namely
Janis et al. (39) and Poggi et al. (45). Meta-analysis with
exclusion of these studies led to an I-squared value of 26%
[0%; 62%], p = 0.19 and a proportion of elimination of 0.41
[0.35; 0.46] (Random-effects model, forest plot not shown, funnel
plot shown in Supplementary Figure 1B). A second sensitivity
analysis excluding the RCTs from the meta-analysis led to a
proportion of 0.38 [0.29; 0.49] of patients with elimination of
MH (Random effects model, I2 = 54.0% [9.1%; 76.7%], p= 0.02,
forest plot not shown). Again, the I-squared value is dependent
on the two outliers formed by Poggi et al. (45) and Janis et al. (39).
With regard to the mean proportion of elimination, Janis et al.
(39) and Poggi et al. (45) report lower elimination rates compared
to the others. However, both studies report substantially higher
percentages of patients having 50–99% improvement compared
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TABLE 2 | Outcome after migraine surgery.
Author(s) (country, year of publication) N treated Elimination (%) Improvement (%) No improvement (%)
Guyuron et al. (USA, 2000) (4) 39 15 (38.5) 16 (41) 8 (20.5)
Guyuron et al. (USA, 2002) (14) 22 10 (45.5) 11 (50) 1 (4.5)
Behin (USA, 2004) (33) 21 9 (42.9) 7 (33.3) 5 (23.8)
Dirnberger and Becker (Austria, 2004) (37) 60 19 (31.7) 16 (26.7) 25 (41.7)
Guyuron et al. (USA, 2005) (42) 89 31 (35) 51 (57) 7 (8)
Poggi et al. (USA, 2008) (45) 18 3 (16.7) 13 (72.2) 2 (11.1)
Guyuron et al. (USA, 2009) (43) 49 28 (57.1) 13 (26.5) 8 (16.3)
Janis et al. (USA, 2011) (39) 24 2 (8.3) 17 (70.8) 5 (20.8)
Gfrerer et al. (USA, 2014) (46) 43 SITES 20 (46.5) 19 (44.2) 4 (9.3)
Guyuron et al. (USA, 2015) (40) 19 10 (52.6) 6 (31.6) 3 (15.8)
Raposio and Caruana (Italy, 2015) (12) 43 17 (39.5) 18 (41.9) 8 (18.6)
Omranifard et al. (Iran, 2016) (44) 25 9 (36.0) 10 (40) 6 (24)
Jose et al. (India, 2017) (41) 30 14 (46.7) 14 (46.7) 2 (6.6)
Gfrerer et al. (USA, 2018) (47) 83 25 (30.0) 43 (52) 15 (18)
Outcome data at follow-up is summarized in this table. In the first column, the number of patients or surgery sites treated with migraine surgery in the study is reported. The second
column states the number of patients with elimination of migraine headache with percentage of total treated patients between brackets. Gfrerer et al. (46) is reported in number of
surgical sites because of lacking individual patient outcomes. The third column reports patients with improvement of symptoms defined as 50–99% improvement of migraine headache
symptoms. Patients reporting <50% or no improvement are reported in the last column.
to the other included studies (Table 2), which might be due to
a stricter handling of the definitions of elimination and strong
improvement and lead to lower elimination proportions. Poggi
et al. (45) included a group of 75–99% improvement and 50% of
the patients ended in this group at follow-up. Janis et al. (39) show
an elimination percentage per individually operated site ranging
from 35% (frontal region) to 62.5% (nasal region), however some
patients did not reach elimination in all trigger sites, which
might influence the final number of patients with full elimination.
The number of patients reporting <50% improvement in both
studies is similar to that of the other included studies. The studies
of Guyuron et al. (43) and Guyuron et al. (40) have a high
elimination rate compared to the others. One aspect in Guyuron
et al. (43) that might contribute to this is that patients only
received one surgery on their most prevalent site of migraine
headache and not receive surgery for other trigger sites. Thus,
the elimination rates were reported after surgery for that specific
site. What is not reported, however, is whether these patients
still had migraine originating from other trigger sites, which
could mean that in some patients the migraine headaches did not
fully disappear but for the mentioned trigger site. Guyuron et al.
(40) compared two surgical approaches at the temporal site and
showed for both approaches a high percentage of elimination.
This could either be due to selection of the patients or perhaps
to a high chance of success of this particular surgical site.
Migraine Surgery vs. Sham or no Surgery at 1-Year
Follow-Up
Three studies performed an RCT comparing surgical treatment
to sham or no surgery, with several notable differences in
methodology. Guyuron et al. (43) compared migraine surgery
to sham surgery; patients were randomly assigned to treatment
groups in a two-third (treatment) vs. one-third (sham) ratio and
patients and investigators (independent of the surgical team)
were blinded to their treatment group until data collection was
finalized. Omranifard et al. (44), randomly assigned patients in
a 1 to 1 ratio and the control group did not receive surgery but
continued standard therapy with medication. Guyuron et al. (42)
randomly assigned patients in a 4 to 1 ratio; control patients were
given a saline injection and did not receive sham surgery, no
data on continued pharmacological treatment during follow-up
period in control patients was given.
The calculated odds ratio for elimination of migraine
headache at 1-year follow-up is 21.46 (random effects model, 95%
CI [5.64–81.58], heterogeneity: I2 = 0% [0%; 62%], p = 0.8396)
for patients receiving migraine surgery compared to sham or no
surgery, shown in Figure 3. Of the 163 patients receiving surgery,
68 (41.7%) reported elimination after 1 year. Of the 70 control
patients, only two patients reported elimination after sham or
no surgery. Of the 163 patients receiving surgical treatment, 21
(12.5%) reported ≤50% improvement of symptoms, considered
to be “no improvement,” compared to 52.8% (37 of 70) of the
control patients. In the study of Guyuron et al. (43), a percentage
of 57.7% of patients reported significant improvement in the
sham group compared to 83.7% in the treatment group. This
high percentage of improvement in the sham group was not
further explained but could be partly due to a rather large placebo
effect. In Guyuron et al. (42) the percentage of improvement
in the sham group was 15.8% (3 of 19 patients). In the study
of Omranifard et al. (44) 40% (10 out of 25) of patients in
the control group (which received only medication treatment)
experienced improvement.
Adverse Events
Several studies reported data on adverse events after surgery
(full list shown in Supplementary Table 2). The most frequent
general adverse events are temporary swelling, numbness, or
shooting pain postoperatively. Less frequent (25–75%) are
temporal hollowing (for the temporal trigger site), immediate
postoperative headache, alopecia and (temporary) ecchymosis.
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The most frequent adverse event for the temporal trigger site
found in Guyuron et al. (43) is temporal hollowing in 53% of
patients. Guyuron et al. (14) reported temporal numbness in all
patients for a period ranging from 1 to 6 months after surgery,
with an average of 2.3 months. In all patients the numbness
recovered. At the nasal trigger site, problems with nasal dryness
or rhinorrhoea and partial recurrence of septal deviation were
reported in Guyuron et al. (42). For the frontal trigger site the
most frequently reported adverse events are itching and hair
loss as reported by Guyuron et al. (42) and Gfrerer et al. (46).
At the occipital trigger point neck stiffness (42) and numbness
(46) were the most common adverse events. At 1-year follow-up
the majority of the listed adverse events had resolved. No major
adverse events were reported.
Assessment of Publication Bias
To assess whether the meta-analysis in Figure 2 suffers
from publication bias, we rendered funnel plots, see
Supplementary Figure 1. For the elimination of migraine
symptoms at 6–12 months follow-up, all included studies are
seemingly randomly dispersed along the funnel axis, with
the exception of Janis et al. (39) and Poggi et al. (45), and
there is no clear indication of publication bias. However, as
described previously these studies reported a smaller proportion
of patients with elimination, most likely due to a stricter
definition of elimination of MH (Supplementary Figure 1B,
outliers excluded). Due to the limited number of studies in the
meta-analysis of the odds ratio for elimination, no funnel plot
was generated.
DISCUSSION
Summary of Main Findings
In this systematic review and meta-analysis of migraine trigger
site surgery, we demonstrate that in selected migraine patients
with identifiable extracranial trigger points, the odds ratio for
elimination of migraine headache after surgery is 21.46 for
surgically treated patients compared to controls. Also, we report
that the average proportion of patients having elimination of
MH post-surgery is 38% after 6–12 months follow-up. In the
remaining proportion of patients that do not experience full
elimination of headaches, there was still a substantial proportion
that reported 50–99% reduction in duration, intensity, and/or
frequency of their headaches. Logically, a significant reduction
of MH (but no elimination) can still lead to considerably less use
of migraine medication and higher quality of life. However, the
documentation of quality of life after migraine surgery is scarce
and has been reported by few groups (5, 42, 50). Given the results
of this study, it is an important factor that should be considered
by future studies investigating the effects of surgery.
Interpretation of Results and Limitations
The endpoints used in migraine surgery trials should be seen in a
separate light from those used in pharmacological migraine trials.
In migraine surgery literature, outcomes are limited to symptoms
related the headache phase. There is currently no data available
describing possible changes in character of the MH after surgery,
which could potentially be an important remaining factor post-
surgery. If migraine surgery cannot fully eliminate the headaches
for a patient, but the MH changes to a more benign form, quality
of life could still be significantly improved. The included studies
are often performed in (mostly female) patients that have tried
many different pharmacological treatments with unsatisfying
result. As a result of this, it is likely that many patients are
prone to medication overuse. A placebo effect can therefore
not be excluded, which also shows from the high percentage of
patients in the sham groups reporting significant improvement
of their MH. The ethical aspects of performing sham surgery in a
randomized surgical trial make this a challenging but important
factor in studying the effectivity of migraine surgery.
Another important factor in this meta-analysis to consider
is the total number of included studies and patients. Low
numbers inevitably alter the reliability of subsequent analyses and
generalizability of found results. However, analysis of confidence
intervals of individual studies included in the analyses was
performed to assess heterogeneity and outliers, as were several
sensitivity analyses to account for the heterogeneity of data.
Especially for the second meta-analysis, caution should be taken
to interpret the calculated odds ratio, given the small I2 value
and the broad confidence interval for I2. This value is due to
the low number of studies that could be included, and should
in this case be interpreted carefully because of risk of bias (51).
Furthermore, regression to the mean is an important effect that
occurs in headache research and cohort studies, especially when
recording pain scores (52). However, considering the relatively
long follow-up time used and the high response rate of study
participants, placebo effect and regression to the mean, although
they can and should not be discarded, are unlikely to be solely
responsible for the treatment effect observed in the prospective
cohorts and randomized trials.
The evidence from the included studies should be viewed
with caution due to limitations in methodology and risk of
multiple forms of bias, including, but not limited to, selection and
observer bias. An important limitation of the included surgical
articles is a lack of transparent patient selection methods with
the obvious risks of selection bias and lack of detailed patient
characteristics before/after surgery. There is often absence of
clearly defined and widely-used outcome measures and accurate
description of pharmacological treatment during the full study
period. Furthermore, the lack of clear definitions for the sham
groups and their (however logical due to ethical considerations)
small group size with uneven allocation of patients to treatment
and control groups leads to a considerable expectancy effect in
the sham groups.
However, despite these clear limitations there is a pressing
need for evaluation of these methods, as migraine surgery is
currently being carried out in a several practices worldwide. This
highlights the necessity for this review, providing a report of the
current standings in literature, and also urges the start of new
well-performed and documented randomized controlled trials in
the future.
Interestingly for example, based on this analysis, compared
to other non-pharmacological treatments for MH such as
transcranial magnetic stimulation (TMS) or transcutaneous
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supraorbital nerve stimulation (t-SNS), the effect size of surgery
is comparable if not larger (53, 54). The important advantage
of surgery over transcranial stimulation approaches, however,
is that patients need to undergo a single episode of surgical
intervention compared to the long-term use of stimulators.
Additionally, an ethical argument for the further study of
headache surgery can be made. In cluster headache, various
surgical approaches are used as a last resort treatment option
when pharmaceutical treatment proves insufficient to relieve
headache symptoms (55). Combined with the results in this
study, the use of surgery and its effectivity for cluster headache
and potentially also migraine headaches may form a basis for
more research into these new applications.
For this meta-analysis, we chose to analyse studies consisting
only of migraine patients undergoing specific surgical treatment.
We selected migraine headache (excluding other headache types
such as cluster headache or (chronic) tension type headache) as a
main focus, in an attempt to demarcate our analysis to a relatively
well-defined population. Furthermore, we only analyzed the
groups with full elimination of MH. This is because many
studies use the migraine headache index (MHI) as their surgical
outcome measurement tool, which is a much-criticized scoring
system for migraine headaches making other categories such as
improvement after surgery hard to assess (28). To improve the
reporting of migraine surgery effects, future studies should focus
instead on describing reduction in headache days and pain scores
for the remaining headache days.
As a result of the factors stated above, the reported odds
ratio and proportion of elimination are only applicable in a
small group of patients. This limitation is outweighed by the
methodological advantages and the higher reliability of the meta-
analysis. This is an important consideration, since the field of
migraine surgery is plagued by many controversies regarding
variation in surgical techniques, description of methodology and
patient selection, as previously stated.
As many reviewers and headache surgery critics
have previously described, poor documentation of these
aforementioned elements is an important limitation that must be
considered when interpreting the data (28, 56–58). Furthermore,
as an example of lacking comparing outcome data, we were
forced to exclude the study of Shevel (5) in the selection process,
which is one of the few studies that describes cauterization of
the extracranial arteries and not decompression as a surgical
approach for MH (5). Interestingly however, a recently published
randomized cohort study from the Guyuron group also argues
that arterectomy in combination with decompression of the
forehead trigger site, gave improved outcomes compared to
the same procedure without arterectomy (59). This adds to the
pathophysiological question which of the structures located at
the trigger site is the key structure to address and the most likely
to cause relief of the migrainous headache phase (60).
CONCLUSIONS
Based on the currently available evidence included in this
review we would cautiously conclude that a subset of selected
migraine patients with distinctly identifiable extracranial MH
trigger sites may benefit from surgical decompression of the
neurovasculature. Important to state is that only a minority of
migraine patients with specific trigger sites may benefit from this
treatment and that current selection procedures for treatment
need optimization and further investigation. Patients are now
often being selected with botulinum toxin in an out-of-standard
dosage. Since migraine surgery is already being employed by
some clinics, albeit on small scale, it is important for both
physicians and patients to critically appraise this treatment and
its effectivity. Standardization of surgical approaches is of key
importance for a further assessment of the real effect of this
treatment (61). Therefore, we urge researchers in the field to
give migraine surgery research a critical but simultaneously
open-minded appraisal and encourage other groups to study
this approach in more detail to ultimately aid in finding better
treatment solutions for the long-time suffering migraine patient.
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Supplementary Figure 1 | Funnel plots for assessment of publication bias. (A)
Funnel plot for Figure 2-Proportion of patients with elimination of MH at follow-up.
X-axis represents the logit transformed proportion of patients with elimination of
headache for each included study. Y-axis represents standard error of study
based on number of included study participants. Outliers can be seen on the
left-hand side of the plot, representing a very low proportion of elimination. (B)
Funnel plot for Figure 2, but with exclusion of two outliers as described in Results
section. Note the narrower area of the funnel due to the exclusion of two outliers.
Supplementary Table 1 | Overview of search terms used per database.
Database search performed on February 17th 2018.
Supplementary Table 2 | Adverse events. Adverse events reported based on
their prevalence reported in the included studies. Superscripted numbers refer to
the respective studies at the bottom of the table. Small numbering used for
respective studies, studies reported as author (year of publication). F, frontal; T,
temporal; N, nasal; O, occipital.
Supplementary Data Sheet 1 | PRISMA 2009 Checklist.
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